Chief Scientific Officer
Dr. Gariépy is a Professor in the departments of Medical Biophysics and Pharmaceutical Sciences at the University of Toronto, the Director of the Molecular Targeting and Therapeutics Laboratory, as well as the SRI Research Chair in Biomolecular Engineering at the Sunnybrook Research Institute in Toronto. Dr. Gariépy was originally trained as a peptide chemist and biophysicist at the University of Alberta and as a peptide/protein engineer at Stanford University in the areas of bacterial toxins and infectious diseases. In 2000, he co-founded Molecular Templates, Inc. (MTI; www.moleculartemplates.com) with Drs. Leigh Revers and Stephen Howard, a biotechnology company that focuses on the development of protein-based biotherapeutics (Engineered Toxin Bodies) in the area of oncology. More recently, Dr. Gariépy went on to co-found D5Pharma.